# N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

> clinical trial · VERIFIED · 2026-07-01

Status: ACTIVE_NOT_RECRUITING · Sponsor: ImmunityBio, Inc. · Condition: Glioblastoma

- Company: ImmunityBio, Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06061809

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.